Concord Wealth Partners Verona Pharma PLC Transaction History
Concord Wealth Partners
- $673 Million
- Q2 2025
A detailed history of Concord Wealth Partners transactions in Verona Pharma PLC stock. As of the latest transaction made, Concord Wealth Partners holds 7 shares of VRNA stock, worth $748. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7Holding current value
$748% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VRNA
# of Institutions
309Shares Held
75.5MCall Options Held
977KPut Options Held
3.12M-
Janus Henderson Group PLC London, X06.13MShares$656 Million0.3% of portfolio
-
Perceptive Advisors LLC New York, NY5.51MShares$589 Million22.87% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y94.13MShares$441 Million16.48% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$362 Million16.88% of portfolio
-
Rtw Investments, LP New York, NY3.05MShares$326 Million4.43% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.52B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...